Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-036281
Filing Date
2025-03-10
Accepted
2025-03-10 16:10:30
Documents
74
Period of Report
2025-01-31

Document Format Files

Seq Description Document Type Size
1 10-Q engn-20250131.htm   iXBRL 10-Q 1738303
2 EX-31.1 engn-ex31_1.htm EX-31.1 22175
3 EX-31.2 engn-ex31_2.htm EX-31.2 21850
4 EX-32.1 engn-ex32_1.htm EX-32.1 11004
5 EX-32.2 engn-ex32_2.htm EX-32.2 11007
  Complete submission text file 0000950170-25-036281.txt   9020848

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20250131.xsd EX-101.SCH 1734358
77 EXTRACTED XBRL INSTANCE DOCUMENT engn-20250131_htm.xml XML 1551994
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-41854 | Film No.: 25723784
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)